Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed. Read my analysis ...

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...

as measured by 6MWD 24 weeks following initiation of treatment. Nine secondary outcome measures were assessed: proportion of participants achieving multicomponent improvement (consisting of ...

Merck , known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background ...

As secondary objectives, the study will also assess the effect of CK-586 on LVEF and NT-proBNP, and determine the candidate .

After six-months follow-up, all seven patients treated with AZD8601 had levels of NT-proBNP – a biomarker ... Despite significant advances in treatment over the last three decades, up to 45% ...

In contrast, increased NT-proBNP levels were observed in hypothyroid patients after treatment (SMD [95%CI] = 1.07[0.28, 1.85]). Conclusion: Thyroid dysfunction can significantly affect NT-proBNP ...

The results of this meta-analysis with 16 cohorts, including 136 089 participants, provided a stable NT-proBNP-AF association. The 2023 guidelines have revised the traditional classification criteria ...

Treatment exposure levels were a significant predictor of the time it takes for NT-proBNP levels to drop below 300 picograms/mL (pg/mL), at which point heart failure is unlikely. For each increase of ...